Efficacy and Safety of Ustekinumab in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Subpopulation Analysis of UNIFI Long-Term Extension through 4 Years
Despite the small sample size which limited data interpretation, long-term UST 90 mg SC treatment is safe and efficacious in Asian patients with moderately to severely active UC demonstrating clinical benefit, consistent with the global population. In addition, Asian patients with relatively stable clinical condition may benefit from UST 90 mg SC when administered in a q12w treatment regimen given its sustained efficacy and low discontinuation rates.
Authors
- Jianmin Zhuo (ORCID: https://orcid.org/0009-0004-6575-6244)
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Colleen W Marano (ORCID: https://orcid.org/0000-0002-4965-5142)
- Shiho Kawamura
- Bryan Wahking (ORCID: https://orcid.org/0000-0001-6016-8209)
- Yuya Imai (ORCID: https://orcid.org/0000-0002-9125-3358)
- Yasuo Suzuki (ORCID: https://orcid.org/0000-0003-3518-5642)
- Hyo Jong Kim (ORCID: https://orcid.org/0000-0002-8761-5571)
- Yoshifumi Ohnishi
- Satoshi Motoya
Institutions
- Toho University (JP)
- Johnson & Johnson (United States) (US)
- Kyorin University (JP)
- Kyung Hee University (KR)
- Sapporo Kosei General Hospital (JP)
- Toho University Medical Center Sakura Hospital (JP)
- Shizuoka Medical Center (JP)
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1159/000549914
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00